Abacus FCF Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Abacus FCF Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.6M	Sell	224,000 -161,100	-42%	-$9.39M	3.06%	4
2025 Q4	$20.8M	Buy	385,100 +8,950	+2%	+$431K	2.71%	6
2025 Q3	$17M	Buy	376,150 +10,740	+3%	+$502K	2.25%	17
2025 Q2	$16.9M	Buy	365,410 +73,911	+25%	+$3.63M	2.37%	15
2025 Q1	$17.8M	Buy	291,499 +88,141	+43%	+$5.14M	2.79%	7
2024 Q4	$11.5M	Buy	203,358 +81,017	+66%	+$4.53M	1.51%	13
2024 Q3	$6.33M	Buy	122,341 +9,496	+8%	+$445K	1.47%	13
2024 Q2	$4.69M	Buy	112,845 +2,440	+2%	+$109K	1.16%	16
2024 Q1	$5.99M	Buy	110,405 +8,095	+8%	+$412K	1.5%	15
2023 Q4	$5.25M	Buy	102,310 +67,856	+197%	+$3.56M	1.52%	11
2023 Q3	$2M	Sell	34,454 -536	-2%	-$32.8K	1.06%	19
2023 Q2	$2.24M	Buy	34,990 +5,076	+17%	+$340K	1.13%	17
2023 Q1	$2.07M	Buy	29,914 +7,986	+36%	+$563K	1.11%	17
2022 Q4	$1.58M	Sell	21,928 -492	-2%	-$37.1K	1.03%	23
2022 Q3	$1.59M	Sell	22,420 -4,075	-15%	-$296K	1.1%	11
2022 Q2	$2.04M	Sell	26,495 -30,564	-54%	-$2.33M	1.25%	15
2022 Q1	$4.17M	Buy	57,059 +32,786	+135%	+$2.2M	1.39%	9
2021 Q4	$1.51M	Hold	24,273	–	–	0.74%	52
2021 Q3	$1.46M	Hold	24,273	–	–	0.71%	53
2021 Q2	$1.62M	Buy	+24,273	New	+$1.58M	0.83%	38

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Abacus FCF Advisors's BMY Position: Q1 2026 in Review

Abacus FCF Advisors reduced its Bristol-Myers Squibb (BMY) stake by 42% in Q1 2026, selling an estimated $9.39M and leaving 224,000 shares worth $13.6M. The position accounts for 3.06% of the portfolio, ranked #4.

Abacus FCF Advisors first reported a position in BMY in Q2 2021 and has held it in 20 quarters since. The position peaked at $20.8M in Q4 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Abacus FCF Advisors held 224,000 shares of Bristol-Myers Squibb worth $13.6M as of Q1 2026.
Abacus FCF Advisors sold 161,100 Bristol-Myers Squibb shares in Q1 2026, an estimated $9.39M.
Bristol-Myers Squibb made up 3.06% of Abacus FCF Advisors's portfolio in Q1 2026, its #4 holding.
Abacus FCF Advisors first reported a position in Bristol-Myers Squibb in Q2 2021 and has held it in 20 quarters since.
Abacus FCF Advisors's Bristol-Myers Squibb position peaked at $20.8M in Q4 2025.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Abacus FCF Advisors's 13F filing for Q1 2026, filed 8 Apr 2026.